2025-10-27T12:17:24-05:00 2024-12-31 812950760 SAX LLP 389 INTERPACE PARKWAY STE 3 PARSIPPANY NJ 07054 990 2024-01-01 920240717 EVERY CURE INC EVER 4842856568 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 DAVID FAJGENBAUM CHAIR, CO-FOUNDER, PRESIDENT 4842856568 2025-10-27 1 0 MARQUS WHITE P00053187 9734726250 2025-10-24 2024 2025-03-06 01:10:19Z X DAVID FAJGENBAUM 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 54466208 0 X WWW.EVERYCURE.ORG X 2022 DE THE ORGANIZATION'S MISSION IS TO SAVE AND IMPROVE LIVES BY REPURPOSING DRUGS. 8 6 16 9 0 0 2433649 54182643 0 0 9736 283565 0 0 2443385 54466208 0 2181501 0 0 116667 3148613 0 0 183495 336135 2104303 452802 7434417 1990583 47031791 3270374 51613641 966302 2337747 2304072 49275894 X EVERY CURE IS A NONPROFIT INITIATIVE ON A MISSION TO UNLOCK THE FULL POTENTIAL OF EXISTING MEDICINES TO TREAT EVERY DISEASE AND EVERY PATIENT THEY POSSIBLY CAN. 0 0 4332726 2181501 1. AI TOOL DEVELOPMENT AND OPEN-SOURCE INITIATIVE (TECHNOLOGICAL INNOVATION)(CONTINUED ON SCHEDULE O)IN 2024, EVERY CURE'S TECHNICAL TEAM BUILT A ROBUST, SCALABLE PLATFORM TO SYSTEMATICALLY IDENTIFY HIGH-POTENTIAL DRUG REPURPOSING OPPORTUNITIES. THE TEAM CURATED COMPREHENSIVE DRUG AND DISEASE LISTS BUILDING ON EXISTING ONTOLOGIES, ESTABLISHED A POWERFUL EXPERIMENTATION AND EVALUATION INFRASTRUCTURE, AND BEGAN THE INTEGRATION OF MULTIPLE PUBLIC AND PROPRIETARY BIOMEDICAL KNOWLEDGE GRAPHS INTO A HARMONIZED ARCHITECTURE. USING THIS FOUNDATION, THEY DEVELOPED AND STABILIZED A PIPELINE THAT ENABLED RAPID, LARGE-SCALE PREDICTION OF DRUG-DISEASE MATCHES, WHICH THEN GO FOR SYSTEMATIC REVIEW BY EVERY CURE'S MEDICAL TEAM. OVER THE COURSE OF THE YEAR, THE TEAM EXECUTED AND LOGGED EIGHT EXPERIMENTS TO VALIDATE AND REFINE MODEL PERFORMANCE, SIGNIFICANTLY ACCELERATING EXPERIMENTAL THROUGHPUT INTO 2025. WE ALSO OBTAINED RIGHTS TO SEVERAL PROPRIETARY DATASETS TO IMPROVE PERFORMANCE IN DIFFERENT STAGES IN THE PIPELINE. 1844784 2. DRUG REPURPOSING RESEARCH AND DEVELOPMENT (SCIENTIFIC APPLICATION)(CONTINUED ON SCHEDULE O)EVERY CURE, INC. SAVES AND IMPROVES LIVES BY REPURPOSING DRUGS. DISCOVERY OF DRUG REPURPOSING OPPORTUNITIES OCCURS USING BOTH EXISTING KNOWLEDGE AND AI-GENERATED FINDINGS. DRUG REPURPOSING EFFORTS ENCOMPASS THE CORE SCIENTIFIC AND MEDICAL EFFORTS TO MOVE A DRUG REPURPOSING CONCEPT FROM DISCOVERY TO CLINICAL APPLICATION. ADVANCEMENT OF THE MOST PROMISING CANDIDATES MAY INCLUDE MANAGING PRE-CLINICAL STUDIES, REAL-WORLD EVIDENCE REVIEW AND CLINICAL TRIALS. IN 2024, EVERY CURE ESTABLISHED A WORLD CLASS MEDICAL TEAM, A TECHNICAL ADVISORY COUNCIL (TAC) AND A SCIENTIFIC ADVISORY COUNCIL (SAC) TO PROVIDE OVERSIGHT AND VALIDATE DISCOVERIES. THE TEAM ESTABLISHED BEST PRACTICE FOR VETTING REPURPOSING OPPORTUNITIES, LEADING TO THE IDENTIFICATION OF FOUR PROMISING REPURPOSED TREATMENTS ENDORSED BY THE SAC AS WELL AS IDENTIFICATION OF POTENTIAL THERAPEUTIC OPPORTUNITIES FOR LONG COVID. THE CANDIDATE DRUG REPURPOSING OPPORTUNITIES SPANNED CONDITIONS FROM A COMMON CANCER TO A RARE NEURODEVELOPMENTAL CONDITIONS. AS A RESULT OF THESE EFFORTS, MULTIPLE INDIVIDUALS SHARED STORIES OF HOW THEIR LIVES WERE SAVED AND IMPROVED BY REPURPOSED DRUGS. 144749 3. EDUCATION AND AWARENESS-RAISING ON DRUG REPURPOSING(CONTINUED ON SCHEDULE O)EVERY CURE, INC. EDUCATES PHYSICIANS, RESEARCHERS, PATIENTS, POLICYMAKERS, AND THE GENERAL PUBLIC ABOUT THE POTENTIAL FOR DRUG REPURPOSING TO ACCELERATE CURES. EDUCATION AND OUTREACH ARE CENTRAL TO CREATING A SHIFT IN MEDICINE, WHERE EXISTING THERAPIES ARE FULLY LEVERAGED FOR DISEASES BEYOND THEIR ORIGINAL APPROVALS.SPECIFIC ACCOMPLISHMENTS INCLUDE: EDUCATIONAL PROGRAMS AND WORKSHOPS: ORGANIZED SCIENTIFIC CONVENINGS SUCH AS THE CHAN ZUCKERBERG INITIATIVE (CZI)-SUPPORTED WORKSHOP ON RARE DISEASE DRUG REPURPOSING, WHICH BROUGHT TOGETHER LEADING EXPERTS ACROSS ACADEMIA, INDUSTRY, AND GOVERNMENT TO SHARE KNOWLEDGE AND DEFINE COLLABORATIVE PATHWAYS. PROFESSIONAL OUTREACH: DISSEMINATED FINDINGS THROUGH PRESENTATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS, INVITED TALKS AT RESEARCH INSTITUTIONS, AND PUBLICATION OF EDUCATIONAL CONTENT IN PROFESSIONAL OUTLETS TO INCREASE AWARENESS AMONG PHYSICIANS AND SCIENTISTS. PATIENT AND PUBLIC ENGAGEMENT: LEVERAGED MEDIA EXPOSURE, SOCIAL MEDIA CAMPAIGNS, AND DIRECT PATIENT COMMUNITY ENGAGEMENT TO INCREASE UNDERSTANDING OF DRUG REPURPOSING OPPORTUNITIES, EMPOWERING PATIENTS TO DISCUSS POTENTIAL OPTIONS WITH THEIR PHYSICIANS. ROADMAP DEVELOPMENT: ADVANCED THE ROADMAP INITIATIVE, A FRAMEWORK FOR HOW TO SYSTEMATICALLY IDENTIFY AND VALIDATE REPURPOSING OPPORTUNITIES FOR RARE DISEASES, PROVIDING A REPLICABLE RESOURCE FOR THE FIELD. DIGITAL AWARENESS: REACHED MILLIONS THROUGH MEDIA FEATURES AND SOCIAL MEDIA, HIGHLIGHTING THE STORY OF DRUG REPURPOSING AND EVERY CURE'S MISSION, INCREASING VISIBILITY AND ENGAGEMENT WITH OUR WORK.THROUGH THESE ACTIVITIES, EVERY CURE HAS CREATED A FOUNDATION OF KNOWLEDGE AND AWARENESS THAT WILL HELP TO ACCELERATE THE PACE OF DRUG REPURPOSING ACROSS THE HEALTHCARE ECOSYSTEM. 6322259 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 18 0 1 16 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY PA X MARY ZUCCATO 4842856568 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 X DAVID FAJGENBAUM PRESIDENT (COMP 9/23-12/24) 30.00 X X 326793 0 0 TANISHA CARINO VICE CHAIR 2.00 X X 0 0 0 TRACEY SIKORA CO-FOUNDER, SECRETARY (THRU 2024) 15.00 X X 0 0 0 ROBERT BATTISTA TREASURER (THRU 2024) 2.00 X X 0 0 0 GRANT MITCHELL CO-FOUNDER,CEO (COMP 9/23-12/24) 40.00 X X 448117 0 17412 FREDA LEWIS-HALL DIRECTOR 1.00 X 0 0 0 ROBERT MCDONALD DIRECTOR 1.00 X 0 0 0 TANIA SIMONCELLI DIRECTOR 1.00 X 0 0 0 ERIC HORVITZ DIRECTOR 2.00 X 0 0 0 JANET WOODCOCK DIRECTOR 1.00 X 0 0 0 MARY ZUCCATO COO (COMP 2/24-12/24) 40.00 X 198737 0 22827 CHARLIE HEMPSTEAD VP OF PLATFORM (COMP 4/24-12/24) 40.00 X 172819 0 29541 ADAM GREEN CHIEF OF STAFF (COMP 2/24-12/24) 40.00 X 108000 0 1938 RICHARD JUDE RIESE CMO (COMP 7/24-11/24) 40.00 X 141805 0 19170 1396271 0 90888 6 0 1 0 AMELIOR CONSULTING LLC 7503 NEWMARKET DR BETHESDA MD 20817 MATRIX CONSULTING 189900 PATZIK FRANK SAMOTNY LTD 200 S WACKER DR STE 2700 CHICAGO IL 60606 LEGAL 159157 2 8846163 45336480 108850 54182643 283565 283565 54466208 0 0 283565 X 2181501 2181501 1326184 875972 450212 1483794 1409188 27766 46840 53748 42611 7586 3551 171971 135400 25143 11428 112916 83718 23512 5686 22400 22400 307446 307446 143309 143309 1631 1631 874155 751550 61530 61075 23430 5827 13853 3750 20889 9028 11861 112565 101268 10560 737 89968 59628 30340 154049 113459 39278 1312 31981 14119 17790 72 12754 10132 2374 248 15366 15366 RECRUITMENT EXPENSE 192781 184659 8122 MISCELLANEOUS EXPENSE 64651 760 15157 48734 RESEARCH & DATA EXPENSE 30000 30000 DUES AND SUBSCRIPTION 5620 5271 349 1308 722 524 62 7434417 6322259 928663 183495 361795 368460 2743659 16902303 150000 29822610 63403 5184 40953 76494 12754 0 63740 4020121 9736 332051 3270374 51613641 284313 2337747 681989 0 966302 2337747 X 2185075 48675894 118997 600000 2304072 49275894 3270374 51613641 X 47031791 -14522 -45447 X 0 1 X 1 0 X 316125 2433649 54182643 56932417 316125 2433649 54182643 56932417 30967256 25965161 9736 283565 293301 57225718 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 76494 12754 63740 63740 X 54489460 -14522 83221 -45447 23252 54466208 0 54466208 7517638 83221 83221 7434417 0 7434417 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. IN ADDITION, THE ORGANIZATION QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER SECTION 170(B)(1)(A) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 509(A)(2). THE ORGANIZATION IS ALSO EXEMPT FROM STATE INCOME TAXES WITHIN THE STATES THAT THE ORGANIZATION OPERATES. THE ORGANIZATION HAS APPLIED THE PROVISIONS OF THE FASB'S ASC 740-10, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. UNDER ASC 740-10, NONPUBLIC ENTERPRISES, INCLUDING NONPROFIT ORGANIZATIONS, ARE REQUIRED TO RECORD A TAX LIABILITY WHEN SUBSTANTIAL UNCERTAINTIES EXIST AS TO WHETHER CERTAIN INCOME IS EXEMPT FROM FEDERAL, STATE AND LOCAL INCOME TAX. AS OF DECEMBER 31, 2024, THE ORGANIZATION HAD NO SUBSTANTIAL UNCERTAIN INCOME TAX POSITIONS. PART XI, LINE 2D - OTHER ADJUSTMENTS: LOSS ON IMPAIRMENT OF ASSETS HELD FOR SALE -45,447. UNITED KINGDOM 1 10 PROGRAM SERVICES RESEARCH AND DEVELOPMENT 1201883 NETHERLAND 0 2 PROGRAM SERVICES RESEARCH AND DEVELOPMENT 338129 1 12 0 0 1 12 1540012 0 1540012 0 0 0 0 0 0 1 PENN STATE UNIVERSITY 180 POLLOCK ROAD 308 OLD MAIN UNIVERSITY PARK PA 16802 246000376 501 (C) (3) 303699 0 PENN STATE WILL LEAD THE DEVELOPMENT OF ADVANCED COMPUTATIONAL TOOLS, INCLUDING ALGORITHMS TO PREDICT DRUG REPURPOSING OPPORTUNITIES WITHIN THE KNOWLEDGE GRAPH. THEY WILL WORK ON DATA EXTRACTION, HARMONIZATION, AND MACHINE LEARNING MODEL DEVELOPMENT TO RANK CANDIDATE DRUGS. THEIR ROLE PROVIDES THE COMPUTATIONAL "ENGINE" THAT DRIVES PRIORITIZATION OF PROMISING THERAPIES. THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501 (C) (3) 362247 0 SCRIPPS WILL INTEGRATE ITS BIOTHINGS EXPLORER PLATFORM INTO EVERY CURE'S KNOWLEDGE GRAPH, CONTRIBUTING APIS, DATA EVALUATION, AND ONTOLOGY MAPPING EXPERTISE. THEY WILL IDENTIFY PROPRIETARY DATASETS, EVALUATE THEIR UTILITY, AND REFINE INTEGRATION PROCESSES FOR CLINICAL AND PATIENT-LEVEL DATA. THEIR WORK STRENGTHENS INTEROPERABILITY AND ENSURES HIGH-VALUE BIOMEDICAL DATA IS CONNECTED ACROSS THE MATRIX PROJECT. UNIVERSITY OF ALABAMA BIRMINGHAM 801 5TH AVE S BIRMINGHAM AL 35233 636005396 501 (C) (3) 235161 0 UAB WILL CONTRIBUTE SPECIALIZED BIOMEDICAL DATA AND EXPERTISE IN INTEGRATING PATIENT-LEVEL, GENOMIC, AND CLINICAL DATASETS INTO THE KNOWLEDGE GRAPH. THEY WILL SUPPORT VALIDATION OF PREDICTED DRUG-DISEASE ASSOCIATIONS THROUGH COMPUTATIONAL AND EXPERIMENTAL METHODS. THEIR WORK ENSURES THE KNOWLEDGE GRAPH IS GROUNDED IN HIGH-QUALITY CLINICAL AND BIOLOGICAL EVIDENCE. UNIVERSITY OF NORTH CAROLINA 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NJ 275991350 566001393 501 (C) (3) 971372 0 UNC WILL CO-LEAD DEVELOPMENT OF THE INTEGRATION LAYER THAT CONNECTS DIVERSE DATASETS INTO A UNIFIED BIOMEDICAL KNOWLEDGE GRAPH. THEY WILL DEFINE ONTOLOGY STANDARDS, CONDUCT MANUAL CURATION, AND LEAD HARMONIZATION ACROSS DRUG, DISEASE, AND MOLECULAR DATA TYPES. THEIR ROLE ENSURES THE ROBOKOP AND MONARCH KNOWLEDGE GRAPHS AND PROPRIETARY DATASETS ARE SYSTEMATICALLY ALIGNED TO EVERY CURE'S COMPUTATIONAL INFRASTRUCTURE. INSTITUTE FOR SYSTEMS BIOLOGY 401 TERRY AVE NORTH SEATTLE WA 98109 912003593 501 (C) (3) 309022 0 ISB WILL CURATE, EVALUATE, AND INTEGRATE LARGE BIOMEDICAL DATASETS INTO EVERY CURE'S KNOWLEDGE GRAPH, FOCUSING ON DATA QUALITY AND ONTOLOGY HARMONIZATION. THEY WILL PERFORM MANUAL CURATION, CROSS-VALIDATION, AND DEVELOPMENT OF PROTOCOLS TO ENSURE RELIABLE DRUG, DISEASE, AND MOLECULAR ASSOCIATIONS. THEIR WORK ENSURES THE SPOKE DATABASE AND OTHER KEY SOURCES ARE INCORPORATED INTO A ROBUST COMPUTATIONAL FRAMEWORK FOR DRUG REPURPOSING. 5 PART I, LINE 2: EVERY CURE IDENTIFIES AND SELECTS GRANT RECIPIENTS BASED ON THEIR UNIQUE, SPECIALIZED EXPERTISE IN SPECIFIC FIELDS OF BIOMEDICAL RESEARCH. THESE INSTITUTIONS WERE CHOSEN TO SERVE AS SUBCONTRACTORS UNDER OUR ARPA-H OTA AGREEMENT TO EXECUTE DEFINED RESEARCH OBJECTIVES. EVERY CURE MONITORS THE DISTRIBUTED FUNDS AND ENSURES THEIR USE FOR PROPER PURPOSES BY TRACKING MILESTONE COMPLETION WITH DIRECT OVERSIGHT FROM THE EVERY CURE PROGRAM TEAM. THE PRIMARY BENEFIT OF THIS WORK ACCRUES TO THE GENERAL PUBLIC, NOT THE FEDERAL GOVERNMENT. X X X 0 0 0 0 0 0 0 0 0 GRANT MITCHELL CO-FOUNDER,CEO (COMP 9/23-12/24) 448117 0 0 0 0 0 5654 0 11758 0 465529 0 0 0 DAVID FAJGENBAUM PRESIDENT (COMP 9/23-12/24) 326793 0 0 0 0 0 0 0 0 0 326793 0 0 0 MARY ZUCCATO COO (COMP 2/24-12/24) 198737 0 0 0 0 0 3715 0 19112 0 221564 0 0 0 CHARLIE HEMPSTEAD VP OF PLATFORM (COMP 4/24-12/24) 172819 0 0 0 0 0 5450 0 24091 0 202360 0 0 0 RICHARD JUDE RIESE CMO (COMP 7/24-11/24) 141805 0 0 0 0 0 5183 0 13987 0 160975 0 0 0 X FURNITURE 1 108850 FMV 0 1 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PRESENTED DURING A MEETING OF THE BOARD OF DIRECTORS TO EACH MEMBER. IT IS REVIEWED, DISCUSSED, AND APPROVED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION ROUTINELY REVIEWS ANY SITUATION THAT ARISES THAT MAY CAUSE A CONFLICT OF INTEREST FORM 990, PART VI, SECTION B, LINE 15 EVERY CURE ENSURES THAT EXECUTIVE COMPENSATION IS REASONABLE AND COMPETITIVE BY FOLLOWING A FORMAL, DOCUMENTED PROCESS. THE INDEPENDENT DIRECTORS OF THE BOARD REVIEW AND APPROVE EXECUTIVE COMPENSATION, IN LINE WITH EVERY CURE'S DEFINED COMPENSATION PHILOSOPHY, ON AN ANNUAL BASIS. IN ACCORDANCE WITH THE COMPENSATION PHILOSOPHY, THE GROUP RELIES ON ROBUST SETS OF COMPARABLE DATA, INCLUDING COMPENSATION STUDIES AND BENCHMARKING FROM REPUTABLE DATABASES AND PUBLICLY AVAILABLE FORM 990 FILINGS FROM SIMILAR ORGANIZATIONS. THE ENTIRE PROCESS, FROM DATA REVIEW TO THE FINAL DECISION, IS DOCUMENTED IN THE OFFICIAL MEETING MINUTES. FORM 990, PART VI, SECTION C, LINE 19 A PACKET IS AVAILABLE UPON REQUEST AT THE ENTITY'S OFFICE. FORM 990, PART VII - ADDITIONAL COMPENSATION INFORMATION GRANT MITCHELL IS ONE OF THE CO-FOUNDERS, AND THE CEO. REPORTED COMPENSATION FOR 2024 INCLUDES 16 MONTHS OF COMPENSATION (9/2023-12/2024), BECAUSE HE WAS PAID IN 2024 FOR 4 MONTHS OF WORK PERFORMED IN 2023 AND 12 MONTHS OF WORK PERFORMED IN 2024. ANNUAL BASE COMPENSATION DURING THIS TIME WAS $350,000. DAVID FAJGENBAUM IS ONE OF THE CO-FOUNDERS, AND PRESIDENT. REPORTED COMPENSATION FOR 2024 INCLUDES 16 MONTHS OF COMPENSATION (9/2023-12/2024), BECAUSE HE WAS PAID IN 2024 FOR 4 MONTHS OF WORK PERFORMED IN 2023 AND 12 MONTHS OF WORK PERFORMED IN 2024. ANNUAL BASE COMPENSATION DURING THIS TIME WAS $234,000. MARY ZUCCATO IS THE COO. REPORTED COMPENSATION FOR 2024 INCLUDES 11 MONTHS OF COMPENSATION (2/2024-12/2024), BECAUSE SHE BEGAN WORK AFTER THE YEAR BEGAN. ANNUAL BASE COMPENSATION DURING THIS TIME WAS $230,000. CHARLIE HEMPSTEAD IS THE VP OF PLATFORM. REPORTED COMPENSATION INCLUDES 9 MONTHS OF COMPENSATION (4/2024-12/2024), BECAUSE SHE BEGAN WORK AFTER THE YEAR BEGAN. ANNUAL BASE COMPENSATION DURING THIS TIME WAS $232,750. RICHARD RIESE IS THE CHIEF MEDICAL OFFICER. REPORTED COMPENSATION FOR 2024 INCLUDES 4 MONTHS OF COMPENSATION (7/2024-11/2024), BECAUSE HE BEGAN WORK AFTER THE YEAR BEGAN AND DISCONTINUED WORK BEFORE THE YEAR ENDED. ANNUAL BASE COMPENSATION DURING THIS TIME WAS $350,000. ADAM GREEN IS THE CHIEF OF STAFF. REPORTED COMPENSATION FOR 2024 INCLUDES 11 MONTHS OF COMPENSATION (2/2024-12/2024), BECAUSE HE BEGAN WORK AFTER THE YEAR BEGAN. ANNUAL BASE COMPENSATION DURING THIS TIME WAS $120,000. FORM 990, PART IX, LINE 11G HR SERVICES: PROGRAM SERVICE EXPENSES 72,455. MANAGEMENT AND GENERAL EXPENSES 19,991. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 92,446. MARKETING: PROGRAM SERVICE EXPENSES 86,450. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 86,450. SUBCONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 592,645. MANAGEMENT AND GENERAL EXPENSES 41,539. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 634,184. STRATEGIC PLANNING: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 61,075. TOTAL EXPENSES 61,075. FORM 990, PART XI, LINE 9: LOSS ON IMPAIRMENT OF ASSETS HELD FOR SALE -45,447.